admin – Page 3114 – Get News Story

Gastroesophageal Reflux Disease Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Cinclus Pharma, Braintree, a part of Sebela Pharma, N-Zyme Biomedical Inc., Phathom Pharma

The Key Gastroesophageal Reflux Disease Companies in the market include – Cinclus Pharma, Braintree, a part of Sebela Pharmaceuticals, N-Zyme Biomedical Inc., Phathom Pharmaceuticals, Sinorda Biomedicine, Sebela Pharmaceutical, Renexxion Ireland, AstraZeneca, Aurobindo Pharma Limited, Cadila Pharmaceuticals Limited, Camber Pharmaceuticals Inc., HK inno.N, Chong Kun Dang Pharmaceutical, Addpharma, Jeil Pharmaceuticals, Renexxion, Daewoong Pharmaceutical, and others.

The Gastroesophageal Reflux Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Gastroesophageal Reflux Disease pipeline products will significantly revolutionize the Gastroesophageal Reflux Disease market dynamics.

DelveInsight’s “Gastroesophageal Reflux Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Gastroesophageal Reflux Disease, historical and forecasted epidemiology as well as the Gastroesophageal Reflux Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Gastroesophageal Reflux Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Gastroesophageal Reflux Disease Market Forecast

Some of the key facts of the Gastroesophageal Reflux Disease Market Report:

The Gastroesophageal Reflux Disease market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
In September 2024, Implantica announced positive two-year results for its RefluxStop device, an implant developed to treat gastro-oesophageal reflux disease (GORD). Presented at the Association of Upper Gastrointestinal Surgery (AUGIS) of Great Britain and Ireland 2024 Conference, the study showed a 90.9% improvement in patients’ quality of life
DelveInsight’s analysis shows that GERD prevalence in North America ranges from 18% to 28%, while in Europe it varies from 9% to 26%, indicating a substantial disease burden in both regions.
Our analysis suggests that the age bracket of 50-59 years exhibits the highest prevalence of GERD, whereas individuals aged 70 years and older have the lowest prevalence. This trend could be linked to age-related alterations in gastrointestinal function, lifestyle choices, and the presence of common health conditions prevalent in older populations.
In France, GERD has an approximate overall prevalence of 31%. The occurrence of frequent GERD is more common among individuals aged over 50 years (10%) compared to those below 50 years (6%). This highlights the importance of age as a factor contributing to GERD prevalence.
Key Gastroesophageal Reflux Disease Companies: Cinclus Pharma, Braintree, a part of Sebela Pharmaceuticals, N-Zyme Biomedical Inc., Phathom Pharmaceuticals, Sinorda Biomedicine, Sebela Pharmaceutical, Renexxion Ireland, Daewoong Pharmaceutical, AstraZeneca, Aurobindo Pharma Limited, Cadila Pharmaceuticals Limited, Camber Pharmaceuticals Inc., CHEPLAPHARM Arzneimittel GmbH, HK inno.N, Chong Kun Dang Pharmaceutical, Addpharma, Jeil Pharmaceuticals, Renexxion, and others
Key Gastroesophageal Reflux Disease Therapies: Vonoprazan, X842, BLI5100, Linaprazan glurate, Naronapride, Fexuprazan, IN-C003, IN-C002, CKD-382, IN-C004, AD-214: , JP-1366, Naronapride, Fexuprazan, and others
The Gastroesophageal Reflux Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Gastroesophageal Reflux Disease pipeline products will significantly revolutionize the Gastroesophageal Reflux Disease market dynamics.

Gastroesophageal Reflux Disease Overview

Gastroesophageal Reflux Disease (GERD) is a chronic digestive disorder where stomach acid or contents flow back into the esophagus, causing irritation and symptoms like heartburn, regurgitation, and chest discomfort. It occurs when the lower esophageal sphincter (LES) weakens or relaxes inappropriately. If untreated, GERD can lead to complications such as esophagitis, ulcers, or Barrett’s esophagus. Management includes lifestyle changes, medications to reduce acid, and in severe cases, surgery.

Get a Free sample for the Gastroesophageal Reflux Disease Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/gastroesophageal-reflux-disease-gerd-market

Gastroesophageal Reflux Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Gastroesophageal Reflux Disease Epidemiology Segmentation:

The Gastroesophageal Reflux Disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Gastroesophageal Reflux Disease
Prevalent Cases of Gastroesophageal Reflux Disease by severity
Gender-specific Prevalence of Gastroesophageal Reflux Disease
Diagnosed Cases of Episodic and Chronic Gastroesophageal Reflux Disease

Download the report to understand which factors are driving Gastroesophageal Reflux Disease epidemiology trends @ Gastroesophageal Reflux Disease Epidemiology Forecast

Gastroesophageal Reflux Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Gastroesophageal Reflux Disease market or expected to get launched during the study period. The analysis covers Gastroesophageal Reflux Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Gastroesophageal Reflux Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Gastroesophageal Reflux Disease Therapies and Key Companies

Vonoprazan: Phathom Pharmaceuticals
X842: Sinorda Biomedicine
BLI5100: Sebela Pharmaceutical
Linaprazan glurate: Cinclus Pharma
Naronapride: Renexxion Ireland
Fexuprazan: Daewoong Pharmaceutical
IN-C003: HK inno.N
IN-C002: HK inno.N
CKD-382: Chong Kun Dang Pharmaceutical
IN-C004: HK inno.N
AD-214: Addpharma
JP-1366: Jeil Pharmaceuticals
Naronapride: Renexxion
Fexuprazan: Daewoong Pharmaceutical

Discover more about therapies set to grab major Gastroesophageal Reflux Disease market share @ Gastroesophageal Reflux Disease Treatment Landscape

Gastroesophageal Reflux Disease Market Strengths

Lifestyle changes, including dietary adjustments, weight management, and elevating the head of the bed, offer non-pharmacological approaches to managing GERD and reducing symptom severity.
There is a growing awareness of GERD among both healthcare professionals and the general population. This increased awareness leads to earlier diagnosis and improved management.

Gastroesophageal Reflux Disease Market Opportunities

Multidisciplinary teams involving gastroenterologists, dietitians, psychologists, and surgeons can work collaboratively to provide comprehensive care and support for GERD patients.
Promising new drugs, such as naronapride, vonoprazan, and BLI5100 are being developed to address GERD and its complications, providing potential alternatives for patients who are unresponsive to current treatments.

Scope of the Gastroesophageal Reflux Disease Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Gastroesophageal Reflux Disease Companies: Cinclus Pharma, Braintree, a part of Sebela Pharmaceuticals, N-Zyme Biomedical Inc., Phathom Pharmaceuticals, Sinorda Biomedicine, Sebela Pharmaceutical, Renexxion Ireland, Daewoong Pharmaceutical, AstraZeneca, Aurobindo Pharma Limited, Cadila Pharmaceuticals Limited, Camber Pharmaceuticals Inc., CHEPLAPHARM Arzneimittel GmbH, HK inno.N, Chong Kun Dang Pharmaceutical, Addpharma, Jeil Pharmaceuticals, Renexxion, and others
Key Gastroesophageal Reflux Disease Therapies: Vonoprazan, X842, BLI5100, Linaprazan glurate, Naronapride, Fexuprazan, IN-C003, IN-C002, CKD-382, IN-C004, AD-214: , JP-1366, Naronapride, Fexuprazan, and others
Gastroesophageal Reflux Disease Therapeutic Assessment: Gastroesophageal Reflux Disease current marketed and Gastroesophageal Reflux Disease emerging therapies
Gastroesophageal Reflux Disease Market Dynamics: Gastroesophageal Reflux Disease market drivers and Gastroesophageal Reflux Disease market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Gastroesophageal Reflux Disease Unmet Needs, KOL’s views, Analyst’s views, Gastroesophageal Reflux Disease Market Access and Reimbursement

To know more about Gastroesophageal Reflux Disease companies working in the treatment market, visit @ Gastroesophageal Reflux Disease Clinical Trials and Therapeutic Assessment

Table of Contents

1. Gastroesophageal Reflux Disease Market Report Introduction

2. Executive Summary for Gastroesophageal Reflux Disease

3. SWOT analysis of Gastroesophageal Reflux Disease

4. Gastroesophageal Reflux Disease Patient Share (%) Overview at a Glance

5. Gastroesophageal Reflux Disease Market Overview at a Glance

6. Gastroesophageal Reflux Disease Disease Background and Overview

7. Gastroesophageal Reflux Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Gastroesophageal Reflux Disease

9. Gastroesophageal Reflux Disease Current Treatment and Medical Practices

10. Gastroesophageal Reflux Disease Unmet Needs

11. Gastroesophageal Reflux Disease Emerging Therapies

12. Gastroesophageal Reflux Disease Market Outlook

13. Country-Wise Gastroesophageal Reflux Disease Market Analysis (2020–2034)

14. Gastroesophageal Reflux Disease Market Access and Reimbursement of Therapies

15. Gastroesophageal Reflux Disease Market Drivers

16. Gastroesophageal Reflux Disease Market Barriers

17. Gastroesophageal Reflux Disease Appendix

18. Gastroesophageal Reflux Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Gastroesophageal Reflux Disease Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Cinclus Pharma, Braintree, a part of Sebela Pharma, N-Zyme Biomedical Inc., Phathom Pharma

Young Tech Entrepreneur Predicted the White-Collar AI Bloodbath – And Built the Solution

“Harshith Vaddiparthy, 22-year-old AI entrepreneur and founder of ARTIFIN.ai, networking at a technology conference. The Y Combinator company JustPaid AI engineer, who successfully exited his AI startup for $50K, discusses the future of work and white-collar job displacement with fellow tech professionals. Vaddiparthy advocates for mastering AI tools like Cursor and Claude to survive the coming automation wave in white-collar industries.”

22-year-old Harshith Vaddiparthy exited AI startup ARTIFIN for $50K and now works at Y Combinator company JustPaid AI. He warns most entry-level jobs are “email jobs using ChatGPT to reply to ChatGPT.” As industry leaders predict AI could eliminate 50% of white-collar jobs within five years, Vaddiparthy offers survival tips: master AI tools like Cursor and Claude, build specialized solutions. His path – no degree, startup exit by 22 – exemplifies thriving in the AI economy.

Jun 2, 2025 – 22-Year-Old Harshith Vaddiparthy, Who Successfully Exited AI Startup, Warns: “Most Entry-Level Jobs Are Just Email Jobs Using ChatGPT to Reply to ChatGPT.”

As industry leaders like Anthropic CEO Dario Amodei warn of an impending “white-collar bloodbath” that could eliminate 50% of entry-level jobs within five years, one young entrepreneur saw this tsunami coming early – and positioned himself as part of the solution. Harshith Vaddiparthy, a 22-year-old AI Product Engineer at Y Combinator company JustPaid AI (YC W23), successfully founded and exited his AI startup ARTIFIN.ai for $50,000 in December 2023, giving him a front-row seat to the very disruption now making headlines across Silicon Valley.

“Most white-collar jobs have become email jobs,” says Vaddiparthy, whose unconventional path of 5+ years professional experience and a successful startup exit before age 22 exemplifies the new breed of tech talent thriving in the AI economy. “We’re literally watching people use ChatGPT to draft replies to emails that were sent using ChatGPT. The irony is staggering.”

THE GREAT DECEPTION: While College Graduates Party, AI Takes Their Jobs

Vaddiparthy’s perspective cuts through the typical doom-and-gloom narrative with brutal honesty about generational preparedness:

“Twenty-somethings just finished college thinking it’s a beautiful world, but they’re about to face reality. The ones who spent four years partying while AI was advancing are now competing for jobs that may not exist in six months.”

His prediction aligns with recent warnings from Anthropic’s Amodei, who told Axios that AI could spike unemployment to 10-20% and eliminate entry-level positions across technology, finance, law, and consulting – exactly the fields recent graduates target.

But Vaddiparthy sees a clear dividing line emerging:

“Only the ones using tools like Cursor, Windsurf, Claude, and ChatGPT are actually going to make it. The future entry-level job isn’t doing the work – it’s using AI tools to create specialized tools for specific use cases.”

THE ARTIFIN SUCCESS STORY: Proof of Concept for the AI-Native Generation

Vaddiparthy’s journey from ambitious young developer to successful AI entrepreneur illustrates his thesis. Working with school friends, he built ARTIFIN.ai, an AI-driven financial analysis platform that he bootstrapped and exited within 18 months.

“We built ARTIFIN because we saw that financial analysis was becoming automated, but firms needed custom AI solutions, not generic chatbots,” explains Vaddiparthy. “The exit gave me runway to experiment with more tools and proved that you don’t need to know how to code anymore – you need to know how to direct AI to code for you.”

Currently serving as AI Growth Marketer at JustPaid AI, a Y Combinator W23 company – and heading Business Development initiavites, Vaddiparthy continues building internal tools that increase productivity and business development efforts – exactly the type of “AI-augmented” roles he predicts will survive the coming automation wave.

THE DEMOCRATIZATION THESIS: Why Traditional Career Paths Are Dead

Vaddiparthy’s analysis goes beyond job displacement to fundamental shifts in how value is created:

“Marketing has been democratized, creativity has been democratized, AI assistants have been democratized. There are thousands of free open-source repos on GitHub that people can leverage. The question isn’t whether AI will replace your job – it’s whether you’ll use AI to create value faster than someone else.”

His perspective challenges both the doomsday scenarios and naive optimism surrounding AI:

“Even top AI scientists don’t know what’s in the AI black box anymore. Everyone is guessing, everyone is going with the flow. But that creates massive opportunities for people who can navigate uncertainty and build practical solutions.”

INDUSTRY VALIDATION: Netflix, Y Combinator, and Global Recognition

Vaddiparthy’s insights aren’t just theoretical. His track record includes:

• Netflix collaboration (Love, Death & Robots project with 131,690 artworks)

• Y Combinator validation through JustPaid AI role

• International recognition as VIP speaker at NewYork Conference 2023

• Leadership roles across multiple AI projects

• Technical expertise spanning React, Node.js, AI/ML

THE SURVIVAL GUIDE: Vaddiparthy’s Roadmap for the AI Economy

Rather than despair, Harshith Vaddiparthy advocates for aggressive adaptation:

1. Tool Mastery Over Domain Knowledge: “Learn Cursor, Windsurf, Claude deeply. These tools are becoming the new literacy.”

2. Build Before You’re Ready: “Don’t wait for permission. Build internal tools, side projects, anything that solves real problems with AI.”

3. Embrace the Meta-Game: “The future isn’t about competing with AI – it’s about using AI to compete with other humans who are also using AI.”

4. Create Niche Solutions: “Everyone’s building general AI tools. The money is in specialized applications for specific industries and use cases.”

THE ECONOMIC REALITY: From Job Security to Value Creation

Vaddiparthy’s perspective reflects a broader shift from traditional employment to value-creation models:

“The whole concept of ‘getting a job’ is becoming obsolete. You need to think like an entrepreneur even if you’re an employee. Your value isn’t your degree or years of experience – it’s your ability to create solutions that didn’t exist yesterday.”

This philosophy aligns with his own journey from ambitious young developer to successful entrepreneur and Y Combinator company engineer in just five years.

LOOKING FORWARD: The Post-Bloodbath Economy

As companies like Microsoft, Walmart, and CrowdStrike announce layoffs citing AI transformation, Vaddiparthy sees opportunity in disruption:

“This isn’t the end of white-collar work – it’s the end of white-collar busy work. The survivors will be people who can think strategically about AI implementation, not just use it to send better emails.”

His advice for young professionals facing an uncertain job market is characteristically direct:

“Stop waiting for someone to give you a career path. Build something, ship it, iterate based on feedback. The AI economy rewards builders, not credential collectors.”

ABOUT HARSHITH VADDIPARTHY

Harshith Vaddiparthy is an AI Product Engineer and Growth Marketer with 5+ years of professional experience despite being only 22 years old. Currently at JustPaid AI (YC W23), he successfully founded and exited ARTIFIN.ai in 2023. His technical expertise spans AI/ML, React, Node.js, and blockchain technologies, with a track record including Netflix collaborations, international speaking engagements, and leadership roles across multiple tech startups.

Website: https://www.harshith.io

Email: vharshith.2810@gmail.com

LinkedIn: https://linkedin.com/in/harshithvaddiparthy

RELATED TOPICS: #WhiteCollarBloodbath #AIJobs #StartupExit #YCombinator #TechEntrepreneur #ArtificialIntelligence #FutureOfWork #AITools #GenZEntrepreneur

SEO KEYWORDS: white collar bloodbath, AI job displacement, startup exit, Y Combinator, Harshith Vaddiparthy, ARTIFIN.ai, AI tools, future of work, tech entrepreneur, job automation

EDITOR’S NOTE: This press release leverages the trending “white-collar bloodbath” topic while positioning Harshith Vaddiparthy as a thought leader who predicted and navigated this transition successfully. The content is optimized for SEO and designed to generate media coverage and professional recognition.

Media Contact
Company Name: ANP Publications
Contact Person: Sarah Pierce
Email: Send Email
Country: United States
Website: https://www.ycombinator.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Young Tech Entrepreneur Predicted the White-Collar AI Bloodbath – And Built the Solution

Green Country Pest Control Announces New Operations Manager

Green Country Pest Control has named Brandon Green as its new Operations Manager, bringing extensive industry experience and a strong track record of growth and operational leadership. Previously VP of Operations at Perfect Pest Control-Texas, Brandon helped triple that company’s customer base and boost revenue by over $2 million in under a year. At Green Country, he is already implementing process improvements aimed at enhancing service quality and operational efficiency.

Alvin, Texas – Jun 2, 2025 – Green Country Pest Control is excited to announce the hiring of Brandon Green as the new Operations Manager. With years of industry experience and a passion for driving operational excellence, Brandon has already begun implementing significant changes that will elevate Green Country Pest Control to new heights. Additionally, the company is proud to promote Colin Banks to Field Supervisor, recognizing his exceptional work and dedication to customer service.

Brandon joins Green Country Pest Control with a proven track record in the pest control industry. He most recently served as Vice President of Operations at Perfect Pest Control-Texas, where he played a key role in tripling the company’s customer base and increasing revenue by over $2 million in just 11 months. His expertise in creating operational procedures and training materials has been invaluable to the success of the organizations he’s worked with.

In his new role, Brandon will focus on streamlining Green Country Pest Control’s operations, improving processes, and enhancing the overall customer experience. His leadership is already transforming the way the company conducts business, and he is committed to fostering growth and setting new standards for pest control services in Alvin and beyond.

“I’m thrilled to be a part of Green Country Pest Control and to contribute to its ongoing success,” said Brandon Green. “I believe in empowering teams, optimizing operational efficiency, and continuously striving for excellence. Together, we will provide top-tier pest control solutions and exceptional service to every customer.”

In addition to Brandon’s appointment, Green Country Pest Control is pleased to announce the promotion of Colin Banks to Field Supervisor. Colin has shown outstanding dedication to the company and its customers, and this promotion recognizes his hard work, leadership skills, and commitment to excellence in the field.

Owner Read Flake expressed his confidence in the company’s future under the new leadership. “Brandon’s extensive experience in the pest control industry, along with Colin’s well-deserved promotion, positions us for continued growth and success. We are excited for what lies ahead under their direction.”

For more information about Green Country Pest Control and its services, please visit www.greencountrypest.com.

Contact:

Green Country Pest Control

Owner: Read Flake

Phone: 281-888-8605

Email: service@greencountrypest.com

Website: www.greencountrypest.com

Media Contact
Company Name: Green Country Pest Control
Contact Person: Read Flake
Email: Send Email
Phone: (281) 888-8605
Address:1600 E Hwy 6 ste 401
City: Alvin
State: Texas
Country: United States
Website: https://www.greencountrypest.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Green Country Pest Control Announces New Operations Manager

Crohn’s Disease Market on Track for Major Expansion by 2034, According to DelveInsight | AbbVie, Merck, Eli Lilly and Company, RedHill Biopharma, Bristol Myers Squibb, Dr. Falk Pharma GmbH, Janssen

The Key Crohn’s Disease Companies in the market include – Merck, Eli Lilly and Company, RedHill Biopharma, Bristol Myers Squibb, Dr. Falk Pharma GmbH, Janssen-Cilag Ltd., AbbVie, EA Pharma Co., Ltd., Erasmus Medical Center, Takeda, Pfizer, Provention Bio, Inc., Mitsubishi Tanabe Pharma Corporation, and others.

The Crohn’s Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Crohn’s Disease pipeline products will significantly revolutionize the Crohn’s Disease market dynamics.

DelveInsight’s “Crohn’s Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Crohn’s Disease, historical and forecasted epidemiology as well as the Crohn’s Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Crohn’s Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Crohn’s Disease Market Forecast

Some of the key facts of the Crohn’s Disease Market Report:

The Crohn’s Disease market size was valued ~USD 10,777 million in 2024 and is anticipated to grow with a significant CAGR of 4.3% during the study period (2020-2034)
In March 2025, Celltrion announced the U.S. launch of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), after receiving FDA approval in December 2024. STEQEYMA is authorized for the same indications as STELARA, ensuring reliable treatment options for both patients and healthcare providers.
In March 2025, Johnson & Johnson announced that the FDA has approved TREMFYA® (guselkumab), making it the first and only IL-23 inhibitor offering both subcutaneous (SC) and intravenous (IV) induction options for adults with moderately to severely active Crohn’s disease (CD), a chronic inflammatory condition affecting the gastrointestinal tract.
In February 2025, Eli Lilly shared findings from the VIVID-2 open-label extension study at the Crohn’s and Colitis Congress (CCC), revealing that most patients with moderately-to-severely active Crohn’s disease treated continuously with OMVOH for two years achieved sustained clinical and endoscopic outcomes, including 43.8% of patients who had previously failed biologic therapies.
In January 2025, The FDA approved OMVOH (mirikizumab) for Crohn’s disease, reinforcing the role of IL-23 inhibitors. Demonstrating robust long-term effectiveness, OMVOH is also under investigation for use in pediatric patients, potentially fulfilling a critical unmet need in this group.
In 2024, the Crohn’s disease market in the US held the largest share among the 7MM, reaching around USD 8,000 million, and it is projected to grow further at a CAGR of 4.5%.
In 2024, Germany recorded the largest Crohn’s disease market size among European nations at approximately USD 670 million, while Spain had the smallest, with around USD 207 million.
In 2024, Japan’s Crohn’s disease market size was estimated at around USD 423 million, representing about 4% of the overall 7MM market.
In 2024, the United States reported approximately 1.1 million diagnosed prevalent cases of Crohn’s disease.
In 2024, the United States accounted for the largest share of diagnosed prevalent Crohn’s disease cases, representing about 54% of the 7MM population, while EU4 and the UK made up roughly 42%, and Japan contributed around 4%.
In 2024, Germany recorded the highest number of diagnosed Crohn’s disease cases among the EU4 countries, with 299,000 cases, followed by the UK with 234,000 cases, while Spain reported the fewest, at 93,000 cases.
In 2024, the United States was estimated to have approximately 461,000 diagnosed prevalent cases of mild Crohn’s disease and around 755,000 cases classified as moderate-to-severe.
Key Crohn’s Disease Companies: Merck, Eli Lilly and Company, RedHill Biopharma, Bristol Myers Squibb, Dr. Falk Pharma GmbH, Janssen-Cilag Ltd., AbbVie, EA Pharma Co., Ltd., Erasmus Medical Center, Takeda, Pfizer, Provention Bio, Inc., Mitsubishi Tanabe Pharma Corporation, and others
Key Crohn’s Disease Therapies: OMVOH (mirikizumab/LY3074828), ENTYVIO (vedolizumab), Tulisokibart (MK-7240, PRA023), Mirikizumab, RHB-104, ZEPOSIA (ozanimod), budesonide, Guselkumab, Risankizumab SC, E6011, Infliximab, CDPATH™, Etrasimod, PRV-6527, MT-1303, and others
In 2023, there were about 432,000 cases classified as mild, and approximately 708,000 cases classified as moderate to severe (including those that transitioned from mild to moderate to severe) in the United States.
The Crohn’s Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Crohn’s Disease pipeline products will significantly revolutionize the Crohn’s Disease market dynamics.

Crohn’s Disease Overview

Crohn’s Disease is a chronic inflammatory condition of the digestive tract that can affect any part from the mouth to the anus. It causes symptoms like abdominal pain, diarrhea, weight loss, and fatigue. The exact cause is unknown, but it involves an abnormal immune response, genetics, and environmental factors. Crohn’s Disease is a type of inflammatory bowel disease (IBD) that can lead to complications such as strictures, fistulas, and malnutrition. Treatment focuses on reducing inflammation, managing symptoms, and maintaining remission.

Get a Free sample for the Crohn’s Disease Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/crohns-disease-cd-market

Crohn’s Disease Epidemiology

Crohn’s Disease Epidemiology Segmentation:

The Crohn’s Disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Crohn’s Disease
Prevalent Cases of Crohn’s Disease by severity
Gender-specific Prevalence of Crohn’s Disease
Diagnosed Cases of Episodic and Chronic Crohn’s Disease

Download the report to understand which factors are driving Crohn’s Disease epidemiology trends @ Crohn’s Disease Epidemiology Forecast

Crohn’s Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Crohn’s Disease market or expected to get launched during the study period. The analysis covers Crohn’s Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report also covers the Crohn’s Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Crohn’s Disease Therapies and Key Companies

OMVOH (mirikizumab/LY3074828): Eli Lilly
ENTYVIO (vedolizumab): Takeda Pharmaceutical
Tulisokibart (MK-7240, PRA023): Merck
AGMB-129: Agomab Therapeutics
TREMFYA: Johnson & Johnson
SKYRIZI + ABBV-382: Abbvie
Mirikizumab: Eli Lilly and Company
RHB-104: RedHill Biopharma
ZEPOSIA (ozanimod): Bristol Myers Squibb
budesonide: Dr. Falk Pharma GmbH
Guselkumab: Janssen-Cilag Ltd.
Risankizumab SC: AbbVie
E6011: EA Pharma Co., Ltd.
Infliximab: Erasmus Medical Center
CDPATH™: Takeda
Etrasimod: Pfizer
PRV-6527: Provention Bio, Inc.
MT-1303: Mitsubishi Tanabe Pharma Corporation
E6011: EA Pharma

Discover more about therapies set to grab major Crohn’s Disease market share @ Crohn’s Disease Treatment Landscape

Crohn’s Disease Market Strengths

Certain initiatives have been taken by private and government organizations to raise awareness about the disease.
Newer, innovative treatments such as JAK inhibitors and immune modulators are being developed. Targeted therapies (mainly biologics) penetration rate in case of moderate to severe Crohn’s Disease patients is expected to be more in future owing to availability of more products with better clinical profile and patient convenient route of administration.

Crohn’s Disease Market Opportunities

Drugs with similar efficacy but better safety profile and patient convenient route of administration are expected to have a significant impact on the Crohn’s Disease market dynamics.
The Crohn’s Disease has complex pathophysiology, including genomes and immune responses, variable clinical manifestations and disease courses, stepwise treatment options, many clinical parameters for monitoring, and unpredictable complications

Scope of the Crohn’s Disease Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Crohn’s Disease Companies: Merck, Eli Lilly and Company, RedHill Biopharma, Bristol Myers Squibb, Dr. Falk Pharma GmbH, Janssen-Cilag Ltd., AbbVie, EA Pharma Co., Ltd., Erasmus Medical Center, Takeda, Pfizer, Provention Bio, Inc., Mitsubishi Tanabe Pharma Corporation, and others
Key Crohn’s Disease Therapies: OMVOH (mirikizumab/LY3074828), ENTYVIO (vedolizumab), Tulisokibart (MK-7240, PRA023), Mirikizumab, RHB-104, ZEPOSIA (ozanimod), budesonide, Guselkumab, Risankizumab SC, E6011, Infliximab, CDPATH™, Etrasimod, PRV-6527, MT-1303, and others
Crohn’s Disease Therapeutic Assessment: Crohn’s Disease current marketed and Crohn’s Disease emerging therapies
Crohn’s Disease Market Dynamics: Crohn’s Disease market drivers and Crohn’s Disease market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Crohn’s Disease Unmet Needs, KOL’s views, Analyst’s views, Crohn’s Disease Market Access and Reimbursement

To know more about Crohn’s Disease companies working in the treatment market, visit @ Crohn’s Disease Clinical Trials and Therapeutic Assessment

Table of Contents

1. Crohn’s Disease Market Report Introduction

2. Executive Summary for Crohn’s Disease

3. SWOT analysis of Crohn’s Disease

4. Crohn’s Disease Patient Share (%) Overview at a Glance

5. Crohn’s Disease Market Overview at a Glance

6. Crohn’s Disease Disease Background and Overview

7. Crohn’s Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Crohn’s Disease

9. Crohn’s Disease Current Treatment and Medical Practices

10. Crohn’s Disease Unmet Needs

11. Crohn’s Disease Emerging Therapies

12. Crohn’s Disease Market Outlook

13. Country-Wise Crohn’s Disease Market Analysis (2020–2034)

14. Crohn’s Disease Market Access and Reimbursement of Therapies

15. Crohn’s Disease Market Drivers

16. Crohn’s Disease Market Barriers

17. Crohn’s Disease Appendix

18. Crohn’s Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Crohn’s Disease Market on Track for Major Expansion by 2034, According to DelveInsight | AbbVie, Merck, Eli Lilly and Company, RedHill Biopharma, Bristol Myers Squibb, Dr. Falk Pharma GmbH, Janssen

Saved By Grace Announces Highly Anticipated New Album, Set for August Release

Erie, Pennsylvania-based Christian rock band signs distribution deal with Sony Music’s The Orchard.

Saved By Grace (SBG), the dynamic Christian rock group hailing from Erie, Pennsylvania, is thrilled to announce the upcoming release of their highly anticipated new album. Produced by Mark Riddell at Edgewater Music Studios in Houston, Texas, this album marks a significant milestone for the band, as it will be distributed through The Orchard of Sony Music Entertainment.

The album, SBG’s third studio effort following the popular “Nashville Recordings” EP, is a collection of eight diverse tracks designed to resonate with a wide range of music enthusiasts. From the hard-hitting energy of “God’s Got Me” to the melodic and uplifting “Your Masterpiece,” the album showcases SBG’s unique blend of alt-rock, blues, and Southern rock influences. As always, Saved By Grace delivers their powerful Gospel message with unwavering passion and authenticity.

The first single from the album is slated for release on June 13th, building anticipation for the full album launch in October. This release is strategically timed to coincide with their 2025 concert series, setting the stage for an extended U.S. tour in 2026. SBG is poised to connect with audiences nationwide, sharing their music and message of hope.

Fans can experience the raw energy and spiritual depth that Saved By Grace brings to their music. The band’s dedication to their craft and their commitment to spreading the Gospel make this album a must-listen for anyone seeking inspiration and powerful rock music. Check out their YouTube channel to see their previous work: https://youtu.be/Y3TsdUxpcUI?si=mEGp0wXCJMbSTyU2

Visit their website for more info about the band, pre-order the album and to visit all of their links. Also, use the contact section to ask questions, schedule interviews, or book a show. https://savedbygracemusic.com

ABOUT

Saved By Grace, a Christian Rock Band, is made up of a talented team of creative musicians who have been performing together since 2021. They pride themselves in spreading the Gospel through Christian Rock music, sharing their love of Jesus through song, and breaking boundaries with their exclusive sound. The band includes Dan Olson (lead vocals), Gill Rice (guitar), Zac Hatch (bass), Jeannette Pattison (BGV), and Michael Shreve (drummer).

LINKS

http://www.savedbygracemusic.com

https://youtu.be/Y3TsdUxpcUI?si=mEGp0wXCJMbSTyU2

https://open.spotify.com/artist/6cq3L5DLQ0MZQCdkFNM7jQ?si=DQ9tUv7pTY-3P5ZAV3VZMg

https://facebook.com/savedbygraceband814

https://instagram.com/savedbygracemusic

https://www.youtube.com/@savedbygracemusic814

@savedbygraceband

Media Contact
Company Name: Saved By Grace Band, LLC
Email: Send Email
Phone: 8148642360
Address:3850 Walker Blvd
City: Erie
State: Pennsylvania 16509
Country: United States
Website: http://www.savedbygracemusic.com/

Chronic Insomnia Market Growth Projections 2023-2032: DelveInsight Analysis | Janssen Research & Development, Takeda

The Key Chronic Insomnia Companies in the market include – Janssen Research & Development, Takeda, and others.

The Chronic Insomnia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Insomnia pipeline products will significantly revolutionize the Chronic Insomnia market dynamics.

DelveInsight’s “Chronic Insomnia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Chronic Insomnia, historical and forecasted epidemiology as well as the Chronic Insomnia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Chronic Insomnia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chronic Insomnia Market Forecast

Some of the key facts of the Chronic Insomnia Market Report:

The Chronic Insomnia market size was valued ~USD 333 million in 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
Among the seven major markets (7MM), the United States represented 67.3% of the total market size for Chronic Insomnia in 2021.
In the 7 MM countries, there will be 5,697,127 cases of chronic insomnia that have been diagnosed as of 2021
Age plays a significant role in how the disease develops. The age group of 20 to 29 years saw the highest number of cases in the US in 2021 with 474,746. Following this, there were 421,996 instances in the US for each of the age groups of 30-39 and 40-49 years
France had the greatest diagnosed prevalence of chronic insomnia among the European nations, with 890,539 cases. Germany came in second with 407,108 cases in 2021
Germany reported 207,625 instances of chronic insomnia in females and 199,483 cases in men among the EU5 nations in 2021
Key Chronic Insomnia Companies: Janssen Research & Development, Takeda, and others
Key Chronic Insomnia Therapies: Seltorexant, Ramelteon and zolpidem, and others
The Chronic Insomnia epidemiology based on gender analyzed that Chronic Insomnia is more prominent in females in comparison to males
The Chronic Insomnia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Insomnia pipeline products will significantly revolutionize the Chronic Insomnia market dynamics.

Chronic Insomnia Overview

Chronic insomnia is a long-term sleep disorder characterized by difficulty falling asleep, staying asleep, or waking up too early, occurring at least three times a week for three months or more. It leads to daytime fatigue, impaired concentration, mood disturbances, and reduced quality of life. Causes can include stress, medical conditions, medications, or poor sleep habits.

Get a Free sample for the Chronic Insomnia Market Report:

https://www.delveinsight.com/report-store/chronic-insomnia-market

Chronic Insomnia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Chronic Insomnia Epidemiology Segmentation:

The Chronic Insomnia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Prevalence of Chronic Insomnia
Prevalent Cases of Chronic Insomnia by severity
Gender-specific Prevalence of Chronic Insomnia
Diagnosed Cases of Episodic and Chronic Chronic Insomnia

Download the report to understand which factors are driving Chronic Insomnia epidemiology trends @ Chronic Insomnia Epidemiology Forecast

Chronic Insomnia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Insomnia market or expected to get launched during the study period. The analysis covers Chronic Insomnia market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report also covers the Chronic Insomnia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Chronic Insomnia Therapies and Key Companies

Seltorexant: Janssen Research & Development
Ramelteon and zolpidem: Takeda

Discover more about therapies set to grab major Chronic Insomnia market share @ Chronic Insomnia Treatment Market

Chronic Insomnia Market Drivers

Increasing Prevalence
Personalization of therapies

Chronic Insomnia Market Barriers

Issues with diagnosis and poor knowledge
Use of off-label drugs
High economic burden

Scope of the Chronic Insomnia Market Report

Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Chronic Insomnia Companies: Janssen Research & Development, Takeda, and others
Key Chronic Insomnia Therapies: Seltorexant, Ramelteon and zolpidem, and others
Chronic Insomnia Therapeutic Assessment: Chronic Insomnia current marketed and Chronic Insomnia emerging therapies
Chronic Insomnia Market Dynamics: Chronic Insomnia market drivers and Chronic Insomnia market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Chronic Insomnia Unmet Needs, KOL’s views, Analyst’s views, Chronic Insomnia Market Access and Reimbursement

To know more about Chronic Insomnia companies working in the treatment market, visit @ Chronic Insomnia Clinical Trials and Therapeutic Assessment

Table of Contents

1. Chronic Insomnia Market Report Introduction

2. Executive Summary for Chronic Insomnia

3. SWOT analysis of Chronic Insomnia

4. Chronic Insomnia Patient Share (%) Overview at a Glance

5. Chronic Insomnia Market Overview at a Glance

6. Chronic Insomnia Disease Background and Overview

7. Chronic Insomnia Epidemiology and Patient Population

8. Country-Specific Patient Population of Chronic Insomnia

9. Chronic Insomnia Current Treatment and Medical Practices

10. Chronic Insomnia Unmet Needs

11. Chronic Insomnia Emerging Therapies

12. Chronic Insomnia Market Outlook

13. Country-Wise Chronic Insomnia Market Analysis (2019–2032)

14. Chronic Insomnia Market Access and Reimbursement of Therapies

15. Chronic Insomnia Market Drivers

16. Chronic Insomnia Market Barriers

17. Chronic Insomnia Appendix

18. Chronic Insomnia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chronic Insomnia Market Growth Projections 2023-2032: DelveInsight Analysis | Janssen Research & Development, Takeda

PINSPARK Graduation Season Special: Setting Sail with Sports Gear to Empower the Class of 2025

As cicadas herald the arrival of summer, a new chapter begins. Global sports gear brand PINSPARK has officially launched its graduation season campaign from May 1 to June 20, 2025, under the theme “Milestone Achievements -Spark Your Future: Celebrate New Beginnings.” The initiative aims to equip the Class of 2025 with professional athletic apparel, transforming graduation into a symbolic starting line for life’s next race. By blending cutting-edge technology with emotional resonance, PINSPARK empowers young graduates to stride confidently into adulthood.

Honoring Growth: A Tribute to Graduation Through Sports Spirit

Graduation season is never just an endpoint; it’s a significant milestone on the path of growth. When the graduation caps are tossed into the air, students have not only completed a stage of their academic journey but are also about to step onto the vast arena called “the future.” PINSPARK deeply understands the unique significance of this moment. With “Milestone Achievements” as its spiritual core, it transforms the resilience, vitality, and self-breaking beliefs inherent in sports into a warm force that accompanies graduates as they open a new chapter in their lives.

During the campaign, PINSPARK is introducing a dedicated graduation season product lineup that covers various scenarios, including running, fitness, and daily travel. From lightweight and breathable sun-protective gear to sports outfits that blend functionality with fashion, all are crafted with cutting-edge fabrics and ergonomic designs to empower the Class of 2025 to confidently tackle every “road condition” on their new life journey.

2025 Graduation Collection: Professional Performance Meets Aesthetic Excellence

This PINSPARK graduation season campaign proudly presents four core products, now available on Amazon, encompassing sportswear, sun-protective shirts, travel outfits, and more, fully meeting the diverse needs of graduates in various scenarios:

【Highlights on the Court】Tennis & Golf Skirt

Featuring a 75% nylon + 25% spandex dynamic support system with built-in anti-exposure shorts lining; a patented V-shaped high-waist cut for dual breakthroughs in sports protection and posture optimization; and a stylish pleated design that allows you to move gracefully and dynamically. Recently honored as the New York Product Design Awards 2025 Winner Silver, this innovative design ensures that whether during daily workouts or pickleball matches, you’ll always stay energetic and enjoy every moment of sports.

【Urban Exploration Gear】Women’s Sun-Protective Short-Sleeve Shirt

Combining UPF50+ sun protection certification with a Morandi color palette, it creates laboratory-grade outdoor protective aesthetics; made of 94% polyester + 6% spandex, enabling seamless transitions from the gym to the café.

【Global Travel Companion】Two-Piece Soft Set

A modular design of 9/10ths length wide-leg pants paired with a short-sleeve shirt, adaptable to multi-climate scenarios between 16-28℃; a fitted cut that accentuates the female silhouette, easy to care for and maintain, perfect for spontaneous graduation trips.

【Endurance Training for Life】High-Waisted Sports Skirt

Designed specifically for tennis. Side hidden pockets for convenient storage of essentials like IDs/phones; a high-waisted tummy-control design that provides support for the waist and abdomen, creating an alluring silhouette. Whether playing pickleball or going for a run, it allows you to fully enjoy sports and focus on sweating it out.

At this moment symbolizing both farewell and departure, PINSPARK uses sports gear as a medium to offer graduates choices that combine practicality with commemorative value. Whether for personal use to commemorate the end of campus life or as a gift for classmates and friends, these four products all embody PINSPARK’s brand DNA, conveying the spirit of “daring to challenge and continuously breaking through,” so that the blessing of “Congrats Grad” is not just in words but becomes a tangible force accompanying users as they cross life’s milestones.

Embark on Your Journey Now: Unlock Your Exclusive Graduation Season Gear

When the solemnity of “Cap And Gown” collides with the vitality of sports, PINSPARK injects unique colors into graduation season with innovative designs. Whether you’re a newcomer to the workforce soon to don formal attire or an explorer setting off on a global journey with a backpack, the PINSPARK graduation season collection will be the best witness to your “Milestone Achievements” with its professional quality and emotional warmth.

This summer, bid farewell to graduation anxiety and ignite your passion for the future in the name of sports! Log in to Amazon, search for PINSPARK, and purchase the 2025 graduation season limited-edition gear to embrace your Next Chapter with confidence.

Media Contact
Company Name: PINSPARK
Contact Person: Charlotte Liu
Email: Send Email
Country: United States
Website: https://pinspark.com

New Historical Novel “Shattered Peace: A Century of Silence” Uncovers a Forgotten Tragedy That Still Echoes Today

A hidden diary. A century-old secret. A haunting legacy of love, war, and betrayal. In her powerful new time-slip novel, Shattered Peace: A Century of Silence, award-winning journalist and author Julie McDonald Zander brings to life a gripping narrative inspired by one of the darkest and least remembered events in American history.

When former Navy Seabee Colleen Holmes inherits her grandmother’s home in Centralia, Washington, she sees it as a fresh start from the trauma of her military service. But her quiet renovation project soon transforms into an unraveling mystery when she discovers an ancestor’s diary and a bundle of love letters buried behind a crumbling wall. As Colleen dives into the story of WWI veteran Michael Dillon and his sweetheart Bridget, she is drawn into the harrowing events surrounding November 11, 1919—when a parade meant to mark peace instead erupted into chaos and bloodshed, leaving the town fractured for generations.

Set against the backdrop of two turbulent time periods—postwar 1919 and the modern day—Shattered Peace explores the cost of silence and the enduring scars of violence, both personal and historical. Through rich historical detail and a deeply emotional narrative, Zander interweaves past and present to reveal a community shaped by what it tried to forget.

Early readers are praising the book’s emotional resonance and historical depth. “A riveting novel inspired by true events,” writes Amazon reviewer Mary E. Trimble. “The story toggles in time between 1919 and 2019… describing the horrors of war and its lasting impact with vivid realism.”

A compelling choice for fans of The Alice Network and The Girl You Left Behind, Shattered Peace is a haunting exploration of resilience, redemption, and the price of truth.

Don’t miss your chance to uncover the secrets that history tried to erase. Shattered Peace: A Century of Silence is available now in paperback and eBook formats—perfect for your next immersive read. Order your copy today on Amazon or Barnes & Noble and experience this unforgettable journey through love, loss, and the echoes of a hidden past. Dive into the mystery—because some stories demand to be told.

Watch the Trailer Now!

Step into the haunting mystery of Shattered Peace: A Century of Silence—where forgotten secrets, forbidden love, and a century-old tragedy collide. Don’t miss the gripping book trailer that brings this powerful story to life.

About the Author

Julie McDonald Zander is an award-winning journalist, historian, and author whose work explores the intersection of personal memory and historical legacy. A graduate of the University of Washington with degrees in communications and political science, Zander spent two decades in newspaper reporting and editing before founding Chapters of Life, her personal history business, through which she has published more than 75 family, community, and organizational biographies.

Her debut novel, The Reluctant Pioneer, was a finalist for the Western Writers of America’s Spur Award for Best Historical Novel. In addition to her work as a personal historian, Zander has served as a regional leader in the Association of Personal Historians, organized major writers’ conferences, and contributed a weekly column to The Chronicle in Centralia, Washington, since 2007. She lives with her husband in the Pacific Northwest, where they raised their two children.

Media Contact
Company Name: Literary Titan
Contact Person: Julie McDonald Zander
Email: Send Email
Country: United States
Website: https://mczander2024.ag-sites.net/index.htm

Pest Me Off Expands Rapid Response Services Amid Rising Rodent Sightings Across Region

Following an unprecedented surge in rodent sightings and pest activity across urban and suburban neighborhoods, Pest Me Off, a leading pest management provider, has announced the expansion of its rapid response services to meet growing regional demand. The company is investing in additional personnel and dispatch units to cut response times and enhance service availability across multiple counties.

McKinney, TX – Recent data collected by local health departments indicate a 36% increase in rodent complaints over the past six months, largely driven by unseasonal weather patterns and urban development disrupting nesting zones. Pest Me Off’s leadership identified this trend as a critical concern for both residential and commercial property owners and acted swiftly to mobilize reinforcements.

“Our mission has always been focused on prevention and safety,” said a spokesperson for the company. “This expansion is designed to deliver immediate solutions in neighborhoods facing urgent pest issues, ensuring safe, sanitary environments.”

As part of the new initiative, Pest Me Off is broadening its service radius to better serve customers searching for pest control near me, especially in newly affected areas previously underserved. The expansion includes specialized technicians trained in handling rodent infestations, termite threats, and insect invasions using eco-conscious methods.

Residents seeking pest and rodent control near me will now benefit from same-day assessments, flexible scheduling, and seasonal pest monitoring plans. The company has also enhanced its digital booking platform to accommodate the influx of service requests and streamline access for both new and returning clients.

With more property owners searching for trusted exterminators close to me, Pest Me Off’s timely expansion positions the company as a critical front-line responder during a period of intensified pest pressure.

For media inquiries, contact 972-866-4765 or visit their website at https://pestmeoff.com/.

Media Contact
Company Name: Pest Me Off
Contact Person: Sam Thornal
Email: Send Email
Address:8751 Collin McKinney Pkwy STE 302
City: McKinney
State: Texas
Country: United States
Website: https://pestmeoff.com/

Residential Home Remodel Contractors in Boca Raton, FL Highlight Client-Centric Approach

Boca Raton, FL – At the heart of the bustling construction industry, ABC Construction Building has established itself as a premier residential home renovation contractor in Boca Raton, FL. The company is known for its dedication to meeting the unique needs of its clients, particularly in the luxury home renovation and home addition segment.

“Client satisfaction drives every decision we make,” Israel Morag, the company’s general contractor, emphasized. “Our aim is to deliver not just to specifications but to exceed expectations in every project we undertake.”

This client-focused approach has earned ABC Construction Building a reputation as a leader in luxury home remodel in Boca Raton, FL. They specialize in not just remodeling a home, but also crafting expansive, upscale additions that not only increase the functionality and aesthetics of homes but also significantly enhance their value.

ABC Construction Building is recognized by many as the best home remodeling contractor in Boca Raton, FL, due to its meticulous attention to detail and commitment to quality. Every phase of the construction process is managed with the utmost care, ensuring that client preferences and budget considerations are prioritized.

As an expert home renovation contractor in Boca Raton, FL, the company maintains an open and consistent line of communication with its clients. This transparency is crucial for building trust and ensuring that every client feels involved and informed throughout the duration of their project.

The team at ABC Construction Building not only meets the industry standards but sets new ones, always aiming to innovate and improve their service offerings. With each project, they strive to ensure that the end result is as unique and individual as their clients themselves.

For homeowners planning to enhance their properties, choosing ABC Construction Building means partnering with a team that values your investment and strives to realize your vision with precision and professionalism. Visit https://abcconstructionbuilding.com/ today to learn more about their services and to schedule a consultation. Start your home transformation journey with a company that truly prioritizes your needs and satisfaction.

Media Contact
Company Name: ABC Construction Building | Home builders in Delray Beach, FL
Contact Person: Israel Morag
Email: Send Email
Phone: +1 561-998-5776
Address:112 SE 10th St
City: Delray Beach
State: Florida 33444
Country: United States
Website: https://abcconstructionbuilding.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Residential Home Remodel Contractors in Boca Raton, FL Highlight Client-Centric Approach